# EDGAR Filing Document

**Accession Number:** 0002072045
**File Stem:** 0002072045-25-000005
**Filing Date:** 2025-6
**Character Count:** 7238
**Document Hash:** d2cce34be39004464e998a72fd21742d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002072045-25-000005.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0002072045-25-000005

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quantum Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001771885
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91661
- **FILM NUMBER:** 251064796

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 55 UNIVERSITY AVENUE, SUITE 1003
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **ZIP:** M5J 2H7
- **BUSINESS PHONE:** (416) 854-8884

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 55 UNIVERSITY AVENUE, SUITE 1003
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **ZIP:** M5J 2H7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FSD Pharma Inc.
- **DATE OF NAME CHANGE:** 20190327
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Malone Wealth Ventures LLC
- **CENTRAL INDEX KEY:** 0002072045

**ORGANIZATION NAME:**
- **EIN:** 861544286
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 9201 W STATE ST. STE 126
- **CITY:** BOISE
- **STATE:** ID
- **ZIP:** 83714
- **BUSINESS PHONE:** 2089854526

**MAIL ADDRESS:**
- **STREET 1:** 9201 W STATE ST. STE 126
- **CITY:** BOISE
- **STATE:** ID
- **ZIP:** 83714

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Quantum Biopharma Ltd.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**74764Y205**

*(CUSIP Number)*

**Malone Wealth Ventures**<br>9201 W State St. Ste 126<br>Boise ID 83714<br>2089854526

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74764Y205** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Malone Wealth Ventures LLC** | Name of reporting person<br>**Malone Wealth Ventures LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**52265.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**610371.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**610371.00** | Aggregate amount beneficially owned by each reporting person<br>**610371.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.8%** | Percent of class represented by amount in Row (11)<br>**17.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** Les Gro

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Quantum Biopharma Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, A6, M5J 2H7

Les Gro

**Item 4. Purpose of Transaction**

The securities were acquired for investment purposes. Kevin Malone serves as Advisor to the Board of Directors of the issuer and may, in such capacity, participate in discussions relating to strategic direction, financing, capitalization, or corporate governance. As such, the Reporting Persons may be deemed to have an intent to influence the control of the issuer.

The Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the securities reported herein, depending on market conditions, investment strategies, or other factors. Except as set forth herein, the Reporting Persons do not currently have any plans or proposals which relate to or would result in any of the actions enumerated in paragraphs (a) through (j) of Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
610,371 17.8%

**(b)**
52265

**(c)**
c. The following transactions in the Common Stock of the issuer were effected by Malone Wealth Ventures LLC on behalf of advisory clients on June 23, 2025. All transactions were open market purchases or sales executed on public exchanges:

June 23, 2025 - Purchased 100 shares at $29.19 per share
June 23, 2025 - Purchased 100 shares at $29.01 per share
June 23, 2025 - Purchased 10 shares at $29.15 per share
June 23, 2025 - Purchased 20 shares at $29.005 per share
June 23, 2025 - Purchased 5 shares at $28.73 per share
June 23, 2025 - Purchased 100 shares at $28.73 per share
June 23, 2025 - Purchased 10 shares at $28.73 per share
June 23, 2025 - Purchased 1000 shares at $27.676 per share
June 23, 2025 - Purchased 300 shares at $27.50 per share
June 23, 2025 - Purchased 230 shares at $26.54 per share
June 23, 2025 - Purchased 4000 shares at $26.596 per share
June 23, 2025 - Purchased 1000 shares at $26.806 per share
June 23, 2025 - Purchased 100 shares at $26.80 per share
June 23, 2025 - Purchased 190 shares at $26.827 per share
June 23, 2025 - Purchased 5000 shares at $25.55 per share
June 23, 2025 - Purchased 300 shares at $25.596 per share
June 23, 2025 - Purchased 1000 shares at $22.18 per share
June 23, 2025 - Sold 5000 shares at $22.549 per share
June 23, 2025 - Purchased 10000 shares at $22.23 per share
June 23, 2025 - Purchased 5000 shares at $23.974 per share

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Malone Wealth Ventures LLC

**Signature:** Kevin M Malone

**Name/Title:** President and CEO

**Date:** 06/23/2025